Andexanet alfa for acute major bleeding episodes requiring reversal of anticoagulation, including reversal of factor Xa inhibition – first line
NIHR HSRIC
Record ID 32016000638
English
Authors' objectives:
Anticoagulants are drugs which prevent the blood from clotting. This can be important for the treatment of some patients, but it also increases the risks of bleeding, which can be very serious or even life-threatening. Andexanet alfa reverses the effects of anticoagulants, allowing the blood to clot normally again in an emergency.
Andexanet alfa is injected directly into the bloodstream of patients who are taking anticoagulants and bleeding.
Andexanet alfa is currently being studied to see how well it works and whether it is safe to use. If andexanet alfa is licensed in the UK, it will offer a new treatment for people with serious bleeding while taking anticoagulants.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hsric.nihr.ac.uk/topics/andexanet-alfa-for-acute-major-bleeding-episodes-requiring-reversal-of-anticoagulation-including-reversal-of-factor-xa-inhibition-first-line/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Blood Coagulation
- Blood Coagulation Factor Inhibitors
- Factor Xa
- Factor Xa Inhibitors
- Fibrinolytic Agents
- Hemorrhage
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.